SecBot SecBot
PRESS-RELEASE ·Filed Jul 21, 2026

DYN

Dyne Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed3mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The offering will dilute existing shareholders by roughly 10%, likely pressuring the stock near term. Monitor the stock's reaction at the open; the $20.50 offering price may act as a near-term floor. Proceeds extend the cash runway for DMD and DM1 clinical programs, reducing near-term financing risk.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.21
T+0 close · Jul 21, 2026 · via day close
Latest settled
−34.12%
T+60 · $15.29
Vs SPY
−37.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $23.21entry
  2. T+1 · 4mo ago +2.93%α +4.16% · $23.89
  3. T+5 · 4mo ago +8.14%α +10.54% · $25.10
  4. T+20 · 3mo ago +15.38%α +12.48% · $26.78
  5. T+60 · 5w ago −34.12%α −37.39% · $15.29
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, raising gross proceeds of $375.15 million. The offering will dilute existing shareholders by approximately 9-11% (including the underwriter option) and provides additional cash runway for the company's clinical-stage neuromuscular programs.

Key Financial Metrics

Deal Value
$375.1M

Key Facts

  • Offering of 18,300,000 shares at $20.50 per share, upsized from original terms.
  • Gross proceeds expected to be $375,150,000 before expenses.
  • Underwriters have a 30-day option to purchase up to an additional 2,745,000 shares.
  • Expected to close on or about July 23, 2026.
  • Joint book-running managers: Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James.

Financial Impact

Gross proceeds of $375.15 million from the sale of 18.3 million shares (plus up to 2.745 million additional shares via underwriter option). Dilution to existing shareholders is significant given the company's pre-revenue status.

dilutioncash position

Risk Factors

  • Significant dilution to existing shareholders (approximately 9.6% base, up to 11% with overallotment).
  • Potential downward pressure on stock price as new shares enter the market.
  • Clinical-stage company with no approved products; offering proceeds may be consumed before reaching key milestones.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3331062

Track record

54 reports on DYN

Performance horizon

12 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 21, 2026